Pricing Log in Create free account
Saturday 7 November 2026 Export NTLA’s income statement to Excel — free account

Intellia Therapeutics, Inc.

NTLA Healthcare Biotechnology

Intellia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.7 million, up 16.9% from fiscal 2024.

Revenue
−48.0%
EPS
+1.09%
Free cash flow
−11.1%

Quarter to September 2026, against a year earlier

11.27 0.17 +1.53%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
−3.4×
Dividend yield
—
F-score
4/9
Altman Z
−1.93
Beneish M
−2.68
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 1.40
Sold, $m 2.25
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — 1 — — — — — — — — — —
Sell 1 7 — 1 — — — 3 1 — 1 1
Insider Ownership 4.46%

Capital & Financial Ratios $m

Size
Market Cap 1,560.00
Revenue ttm 52.89
Net income ttm (426.14)
Free cash flow ttm (355.17)
Net debt Q (474.11)
Valuation
P/E 0.00
Forward P/E (3.35) (negative: loss-making)
Price / sales 29.87 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.58
Financial health
Current ratio Q 6.31 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (10.29)
Growth
Revenue growth Q −48.03% (below 0%: shrinking)
Operating income growth Q −9.73% (below 0%: shrinking)
EPS, this year +15.48% (at or above 15%: strong)
EPS, next year A +17.89% (at or above 15%: strong)
Revenue, next year A −41.36% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +23.42% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 20.9×, against a ten-year median of 21.3×; over the ten years it ranged from −6.7× in 2016 to 339× in 2021.
P/S against its own 10 years 44.63%
10-year low 10-year high
P/B against its own 10 years 43.63%
10-year low 10-year high
EV/Sales against its own 10 years 49.19%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 912 602 450 474
Receivables 36 9 9 7
Inventory — — — —
Other — — — —
998 640 528 506
2023 2024 2025 Q'26
Payables 7 15 20 13
ST’ Debt — — — —
Other — — — —
115 111 104 80

Compound Annual Growth %

10y 5y 3y
Sales 27.32% 3.13% 9.09%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 4.96% (18.40%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.82 Actual −0.91

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.99 −0.83 Beat by 0.16
Q1 FY26 −0.92 −0.81 Beat by 0.11
Q2 FY26 −0.80 −0.80 Met by 0.00
Q3 FY26 −0.82 −0.91 Miss by 0.09
Q4 FY26 −0.77 — Reports 25 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.81) (0.80) (0.91) — —
’25 (1.10) (0.98) (0.92) (0.83) (3.81)
’24 (1.12) (1.52) (1.34) (1.27) (5.25)
’23 (1.17) (1.40) (1.38) (1.46) (5.42)
’22 (1.96) (1.33) (1.49) (1.40) (6.16)
’21 (0.69) (1.01) (0.97) (1.09) (3.78)
’20 (0.63) (0.61) (0.47) (0.69) (2.40)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 15 8 7 — —
’25 17 14 14 23 68
’24 29 7 9 13 58
’23 13 14 12 (2) 36
’22 11 14 13 14 52
’21 6 7 7 13 33
’20 13 16 22 7 58
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (117) (83) (85) — —
’25 (149) (100) (77) (69) (395)
’24 (121) (58) (85) (85) (349)
’23 (109) (90) (101) (93) (394)
’22 (80) (85) (79) (90) (333)
’21 (52) (53) (65) (55) (225)
’20 (39) 57 (29) (40) (50)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (117) (85) (85) — —
’25 (150) (100) (77) (69) (396)
’24 (123) (59) (86) (86) (355)
’23 (113) (95) (106) (95) (408)
’22 (81) (89) (83) (94) (347)
’21 (55) (56) (70) (58) (238)
’20 (39) 56 (29) (41) (53)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 16 26 30 43 58 33 52 36 58 68 53 +17.0% 40 137 418 +83.5%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.0 pt
EBT (32) (68) (85) (100) (134) (268) (474) (481) (519) (413) (426) +33.0%
EBT margin, % (191.97) (258.62) (280.42) (230.92) (231.46) (810.49) (909.78) (1,326.51) (896.77) (609.85) (805.75) (417.9) pt
Net income (32) (68) (85) (100) (134) (268) (474) (481) (519) (413) (426) +33.0%
Per share, $
Per share, $ Revenue 0.74 0.73 0.71 0.91 1.04 0.47 0.68 0.41 0.59 0.62 0.38 (1.9%)
Earnings (1.42) (1.88) (1.98) (2.11) (2.40) (3.78) (6.16) (5.42) (5.25) (3.81) (3.35) +11.6%
Cash flow 1.62 (1.81) (1.42) (2.19) (0.89) (3.17) (4.33) (4.44) (3.53) (3.64) (2.53) n/m
Capex (0.28) (0.28) (0.14) (0.14) (0.06) (0.18) (0.17) (0.16) (0.06) (0.01) 0.00 (30.6%)
Free cash flow 1.35 (2.09) (1.57) (2.33) (0.96) (3.35) (4.50) (4.60) (3.59) (3.65) (2.53) n/m
Book value 9.44 8.35 6.45 5.71 9.41 14.67 16.05 11.83 8.82 6.20 4.37 (4.6%)
Shares, m 22 36 43 47 56 71 77 89 99 108 125 +19.3%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 18.18 29.65 19.32 16.08 52.52 253.61 54.00 76.86 19.91 14.40 29.87 55.5
P/B 1.43 2.58 2.12 2.57 5.78 8.06 2.28 2.65 1.32 1.45 2.58 3.0
EV/Sales 1.61 16.61 9.00 9.59 42.22 230.96 31.12 51.71 9.52 7.75 20.91 41.0
EV/FCF 0.88 (5.76) (4.06) (3.76) (45.77) (32.10) (4.68) (4.60) (1.55) (1.32) (3.10) (10.3)
Cash, $m
Cash, $m Operating cash flow 36 (65) (61) (103) (50) (225) (333) (394) (349) (395) (355) n/m
Capex (6) (10) (6) (7) (4) (13) (13) (14) (6) (1) (2) (17.2%)
Free cash flow 30 (75) (67) (110) (53) (238) (347) (408) (355) (396) (355) n/m
Balance, $m
Balance, $m Working capital 251 323 284 254 552 643 1,090 883 529 424 426 +6.0%
Net debt (273) (341) (314) (280) (597) (749) (1,193) (912) (602) (450) (474) +5.7%
Shareholders’ equity 210 301 278 270 527 1,040 1,236 1,050 872 671 613 +13.8%
Returns, %
Returns, % ROA (16.60) (20.01) (23.59) (29.21) (26.56) (27.19) (33.69) (34.11) (41.66) (40.60) (46.63) (24.0) pt
ROIC 0.00 0.00 0.00 0.00 0.00 (57.42) (666.53) (233.47) (123.47) (124.43) (195.32) (124.4) pt
ROE (33.54) (26.46) (29.50) (36.34) (33.69) (34.18) (41.67) (42.10) (54.00) (53.48) (62.60) (19.9) pt
People
People Employees 104 195 211 270 312 485 598 526 403 377 — +15.4%
Revenue/emp, $m 0.16 0.13 0.14 0.16 0.19 0.07 0.09 0.07 0.14 0.18 — +1.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Intellia Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ABSI Absci Corporation $1.6B — (loss-making) — (loss-making) −46.37% (below 0%: shrinking) n/m −71.74% (below 0%: shrinking) 100.00% (10,741.51%) Compare
GENB Generate Biomedicines, Inc. $1.6B — (loss-making) — (loss-making) — n/m −224.24% (below 0%: shrinking) 100.00% (1,134.21%) Compare
NVAX Novavax, Inc. $1.6B — (loss-making) 110× −3.05% (below 0%: shrinking) n/m −189.09% (below 0%: shrinking) 65.61% (45.80%) Compare
SLS SELLAS Life Sciences Group, Inc. $1.6B — (loss-making) — (loss-making) −57.10% (below 0%: shrinking) n/m −3.52% (below 0%: shrinking) 0.00% 0.00% Compare
KLRA Kailera Therapeutics, Inc. $1.6B — (loss-making) — — n/m −325.95% (below 0%: shrinking) — 0.00% Compare
BRVE Braveheart Bio, Inc. $1.6B — — — n/m — — 0.00% Compare
NTLA Intellia Therapeutics, Inc. $1.6B — (loss-making) — (loss-making) −48.03% (below 0%: shrinking) n/m −11.05% (below 0%: shrinking) 100.00% (1,707.73%)
RARE Ultragenyx Pharmaceutical Inc. $1.5B — (loss-making) — (loss-making) +8.13% (above 0%: growing) n/m +12.50% (above 0%: growing) 81.50% (63.58%) Compare
NBTX Nanobiotix S.A. - Sponsored ADR $1.5B — (loss-making) — −71.69% (below 0%: shrinking) n/m −177.26% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $1.6B — — −46.37% — −177.26% 73.55% (22.90%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 5.06m 3.24m 16.53
2024 15.33m 353.49k 21.43
2023 11.66m 8.32m 56.05
2022 10.10m (14.07m) 64.14
2021 9.77m 37.78m 217.35

Ownership

Directors and executive officers, together 3.50%
ARK Investment Management LLC 11.80%
The Vanguard Group 10.80%
BlackRock, Inc. 7.00%
State Street Corp 5.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Intellia Therapeutics, Inc. (NTLA) Latest News

6 Nov

Impact 3 · · Zacks

5 Nov

Impact 4 · · GlobeNewswire

29 Oct

Impact 4 · · GlobeNewswire

28 Oct

Impact 4 · · GlobeNewswire

18 Oct

Impact 4 · · Simply Wall St.

13 Oct

Impact 4 · · GlobeNewswire

9 Oct

Impact 4 · · Zacks

2 Oct

Impact 3 · · GlobeNewswire

29 Sep

Impact 4 · · Barchart

22 Sep

Impact 4 · · Simply Wall St.

19 Sep

Impact 4 · · MarketBeat

18 Sep

Impact 3 ·

17 Sep

Impact 4 ·

10 Sep

Impact 4 ·

9 Sep

Impact 4 ·

8 Sep

Impact 4 · · Stocktwits
Impact 4 · · InvestorsHub
Impact 4 ·

5 Sep

Impact 4 ·
Impact 3 ·

4 Sep

Impact 4 ·

13 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 4 · · biopharmadive.com
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat transcript

6 Aug

Impact 4 · transcript
Impact 3 ·
Impact 3 ·

9 Jul

Impact 4 ·

8 Jul

Impact 4 · · The Motley Fool
stockrow.com/NTLA · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com